Long Shortz with AROA Biosurgery: Delighted with full year results on Myriad of sales
Stockhead TV
share
Stockhead’s Sarah Hughan sits down with AROA Biosurgery (ASX:ARX) founder and CEO Brian Ward to get the short end of the long story on the company’s latest news.
The soft-tissue regeneration company released its FY24 financial results with a total revenue of NZ$69.1M, buoyed by sales of its Myriad wound-healing innovations.
It’s also looking to commercialise its Enivo device with an estimated market opportunity in excess of US$1B.
Tune in to hear AROA Biosurgery’s Brian Ward on the financial highlights, its growing portfolio, and more.
